8-K: Aprea Therapeutics Doses First Patient in Phase 1 Trial of Oral WEE1 Inhibitor APR-1051

Aprea Therapeutics has announced the dosing of the first patient in its Phase 1 clinical trial evaluating the oral WEE1 inhibitor APR-1051 for advanced solid tumors.

Summary

• Aprea Therapeutics has initiated a Phase 1 clinical trial, ACESOT-1051, for its oral WEE1 inhibitor, APR-1051.
• The trial is designed to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of APR-1051 as a monotherapy in patients with advanced solid tumors.
• The study will enroll up to 79 patients and is divided into two parts: dose escalation and dose optimization.
• The first patient was dosed on June 17, 2024, at NEXT Oncology in San Antonio, Texas.
• Aprea expects to provide a clinical update by the end of 2024 and generate preliminary efficacy data during 2025.
• APR-1051 is a highly selective small molecule designed to limit off-target toxicity and has shown favorable drug exposure in preclinical models.
• The company also updated its corporate presentation slide deck on June 17, 2024.
• Aprea's lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor, with a Phase 1/2a trial ongoing.

Sentiment

Score: 7

Explanation: The document is positive due to the initiation of a new clinical trial and promising preclinical data, but there are still risks associated with drug development and the need for additional funding.

Positives

• The initiation of the Phase 1 trial for APR-1051 is a significant milestone for Aprea's clinical pipeline.
• APR-1051 has shown promising preclinical results, including high selectivity and favorable drug exposure.
• The biomarker-driven approach of the ACESOT-1051 trial may lead to more targeted and effective treatments.
• Aprea's ATR inhibitor, ATRN-119, is showing promising results with no dose-limiting toxicities reported to date.
• The company has a diversified portfolio with both ATR and WEE1 inhibitors in development.
• Aprea has a strong intellectual property portfolio with multiple patents protecting its lead molecules.

Negatives

• The company is still in the early stages of clinical development for both APR-1051 and ATRN-119.
• There are no head-to-head studies comparing APR-1051 with other WEE1 inhibitors.
• The company is dependent on additional financing to fund its operations and complete the development of its product candidates.
• The company has a limited history and the assets were acquired from Atrin Pharmaceuticals Inc.

Risks

• The success of the clinical trials for APR-1051 and ATRN-119 is not guaranteed.
• The company may face challenges in enrolling patients in its clinical trials.
• There are risks associated with the development and commercialization of new drugs, including regulatory hurdles and market acceptance.
• The company's financial position is dependent on raising additional capital.
• The company is subject to risks related to the interpretation of preclinical and early clinical results.

Future Outlook

Aprea plans to provide a clinical update on the APR-1051 trial by year-end 2024 and generate preliminary efficacy data during 2025. The company also anticipates potential efficacy data for ATRN-119 in the second half of 2024 and is financed into the third quarter of 2025.

Management Comments

• Oren Gilad, Ph.D., President and CEO of Aprea, stated that dosing the first patient in the ACESOT-1051 study is an important milestone and represents a key advancement of their clinical pipeline.
• Anthony Tolcher M.D., Founder of Next Oncology, commented that they are committed to exploring new treatment options for cancer patients and are pleased to begin this important clinical trial.

Industry Context

The development of WEE1 and ATR inhibitors is part of a broader trend in precision oncology, focusing on targeted therapies that exploit specific vulnerabilities in cancer cells. Aprea's approach aligns with the industry's move towards synthetic lethality and DNA damage response pathways as key targets for cancer treatment.

Comparison to Industry Standards

• Aprea's APR-1051 is being developed as a potentially best-in-class WEE1 inhibitor, aiming to address the tolerability issues seen with other WEE1 inhibitors like AstraZeneca's Adavosertib (AZD-1775), which was discontinued due to its tolerability profile.
• The company is also differentiating its ATR inhibitor, ATRN-119, by using a macrocyclic structure, which they believe will improve selectivity and tolerability compared to first-generation acyclic ATR inhibitors like those from AstraZeneca (AZD6738), Bayer (BAY1895344), and Repare (RP-3500).
• The company is targeting specific biomarkers such as CCNE1, CCNE2, FBXW7, PPP2R1A, and KRAS-G12 with TP53, which is a common approach in precision oncology to improve the efficacy of treatments.

Stakeholder Impact

• Shareholders may view the initiation of the Phase 1 trial as a positive development.
• Patients with advanced solid tumors may benefit from the development of new treatment options.
• Employees of Aprea are involved in the development and execution of the clinical trials.
• The company's suppliers and partners may be impacted by the progress of the clinical trials.

Next Steps

• Aprea will continue enrolling patients in the ACESOT-1051 Phase 1 trial.
• The company plans to provide a clinical update on the APR-1051 trial by year-end 2024.
• Aprea expects to generate preliminary efficacy data for APR-1051 during 2025.
• The company anticipates potential efficacy data for ATRN-119 in the second half of 2024.

Key Dates

Keywords

WEE1 inhibitor, APR-1051, ATR inhibitor, ATRN-119, clinical trial, synthetic lethality, precision oncology, cancer, DNA damage response, biomarker, solid tumors